Adicet Bio (LTS:0HX7) Dividend Payout Ratio: (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0HX7 Adicet Bio Inc LTS:0HX7
23 GF Score
Price $8.82
GF Value $0.45
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Adicet Bio Dividend Payout Ratio?

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Adicet Bio's Dividend Payout Ratio for the months ended in Jun. 2026 was .

The historical rank and industry rank for Adicet Bio's Dividend Payout Ratio or its related term are showing as below:


LTS:0HX7's Dividend Payout Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 0.4
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2026-09-22), the Dividend Yield % of Adicet Bio is 0.00%.

Adicet Bio's Dividends per Share for the months ended in Jun. 2026 was $.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Adicet Bio (LTS:0HX7) Dividend Payout Ratio Explanation

In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Adicet Bio Dividend Payout Ratio Related Terms

Adicet Bio Dividend Payout Ratio Historical Data

* Premium members only.

The historical data trend for Adicet Bio's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adicet Bio Dividend Payout Ratio Chart

Adicet Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Dividend Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Adicet Bio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Dividend Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

LTS:0HX7 vs OKYO, GOSS, ACRV: Dividend Payout Ratio Comparison

For the Biotechnology subindustry, Adicet Bio's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adicet Bio Dividend Payout Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adicet Bio's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Adicet Bio's Dividend Payout Ratio falls into.


LTS:0HX7
23GF Score
Adicet Bio Inc LTS:0HX7
Dividend Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adicet Bio Dividend Payout Ratio Calculation

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.

Adicet Bio's Dividend Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Dividend Payout Ratio=Dividends per Share (A: Dec. 2025 )/ EPS without NRI (A: Dec. 2025 )
=/ -16.949253381347
=N/A

Adicet Bio's Dividend Payout Ratio for the quarter that ended in Jun. 2026 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Jun. 2026 )/ EPS without NRI (Q: Jun. 2026 )
=/ -1.9876129222945
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Adicet Bio (LTS:0HX7) Overvalued in 2026?

Based on GuruFocus' analysis, Adicet Bio stock appears to be overvalued. The current stock price of $8.82 is trading 1860.3% above its estimated GF Value™ of $0.45. GuruFocus considers Adicet Bio to be Significantly Overvalued.

Key valuation signals for LTS:0HX7:

  • Dividend Payout Ratio:
  • GF Value™: $0.45 vs. price of $8.82 (1860.3% above fair value)
  • GF Score™: 23/100 with 2 warning signs

No single metric tells the full story. See the LTS:0HX7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adicet Bio Business Description

Other Exchanges ACET:USA
Address 131 Dartmouth Street, 3rd Floor, Boston, MA, USA, 02116
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
23GF Score

Get the complete analysis for LTS:0HX7

Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.82
Price
$0.45
GF Value